Garcia, Giani Martins; Roy, Jérôme; Pitta, Ivan R; Abdalla, Dulcinéia Saes Parra 
; Guimarães, Andrea Grabe ; Mosqueira, Vanessa Carla Furtado ; Richard, Sylvain
Fonte: Pharmaceutics. Unidade: FCF
Assuntos: NANOPARTÍCULAS, ARTERIOSCLEROSE, SÍNDROME X METABÓLICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GARCIA, Giani Martins et al. Polylactide nanocapsules attenuate adverse cardiac cellular effects of Lyso-7, a Pan-PPAR agonist/anti-inflammatory new thiazolidinedione. Pharmaceutics, v. 13, p. 1-13 art. 1521, 2021Tradução . . Disponível em: https://doi.org/10.3390/pharmaceutics13091521. Acesso em: 09 nov. 2024.APA
Garcia, G. M., Roy, J., Pitta, I. R., Abdalla, D. S. P., Guimarães, A. G., Mosqueira, V. C. F., & Richard, S. (2021). Polylactide nanocapsules attenuate adverse cardiac cellular effects of Lyso-7, a Pan-PPAR agonist/anti-inflammatory new thiazolidinedione. Pharmaceutics, 13, 1-13 art. 1521. doi:10.3390/pharmaceutics13091521NLM
Garcia GM, Roy J, Pitta IR, Abdalla DSP, Guimarães AG, Mosqueira VCF, Richard S. Polylactide nanocapsules attenuate adverse cardiac cellular effects of Lyso-7, a Pan-PPAR agonist/anti-inflammatory new thiazolidinedione [Internet]. Pharmaceutics. 2021 ; 13 1-13 art. 1521.[citado 2024 nov. 09 ] Available from: https://doi.org/10.3390/pharmaceutics13091521Vancouver
Garcia GM, Roy J, Pitta IR, Abdalla DSP, Guimarães AG, Mosqueira VCF, Richard S. Polylactide nanocapsules attenuate adverse cardiac cellular effects of Lyso-7, a Pan-PPAR agonist/anti-inflammatory new thiazolidinedione [Internet]. Pharmaceutics. 2021 ; 13 1-13 art. 1521.[citado 2024 nov. 09 ] Available from: https://doi.org/10.3390/pharmaceutics13091521
